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SUMMARY
1. Fabry disease results from an X-linked mutation in the
lysosomal -galactosidase A (Gla) gene. Defective Gla results in
multi-organ accumulation of neutral glycosphingolipids (GSLs),
especially in the vascular endothelium, with the major GSL
accumulated being globotriaosylceramide (Gb3). Excessive
endothelial Gb3 accumulation is associated with increased
thrombosis, atherogenesis and endothelial dysfunction. How-
ever, the mechanism(s) by which endothelial dysfunction occurs
is unclear. The purpose of the present study was to further
characterize the vasculopathy associated with a murine model
of Fabry disease.
2. Vascular reactivity was performed in vessels from wild-
type (Gla+/0) and Gla-knockout (Gla–/0) mice. Conscious blood
pressure and heart rate were measured in Gla+/0 and Gla–/0 mice
by telemetry.
3. The present study demonstrates that vascular smooth
muscle (VSM) contractions to phenylephrine and serotonin,
but not to U46619, were blunted in Gla–/0 mice. Endothelium-
dependent contraction and receptor-mediated endothelium-
dependent relaxation to acetylcholine were significantly attenuated
in vessels from Gla–/0 mice. However, receptor-independent
endothelium-dependent relaxation to the calcium ionophore
ionomycin remained intact in vessels from Gla–/0 mice. Further-
more, VSM reactivity was normal in aortas from Gla–/0 mice in
the absence of endothelium. These changes in vascular function
were observed without changes in whole-animal blood pressure
or heart rate.
4. These results suggest that the vasculopathy associated
with Fabry disease is localized to the endothelium, despite the
accumulation of GSLs throughout the vasculature.
Key words: endothelium, Fabry disease, -galactosidase A,
globotriaosylceramide.
INTRODUCTION
Fabry disease, a rare lysosomal storage disorder, results from a
deficiency in the lysosomal hydrolase -galactosidase A (Gla).1,2
The multi-organ accumulation of neutral glycosphingolipids (GSLs)
with -galactosyl linkages, primarily globotriaosylceramide (Gb3),
is the consequence of deficient lysosomal Gla activity.3,4 Because the
disease is a recessive X-linked disorder, hemizygous males are more
severely affected by the disease and premature mortality is the result
of the development of renal insufficiency and end-stage renal dis-
ease, as well as cardiovascular and cerebrovascular complications.5,6
The basis for these cardio- and cerebrovascular complications
associated with Fabry disease may be derived, in part, from endothelial
dysfunction associated with Gb3 accumulation in vascular endothe-
lium. To date, previous studies have demonstrated Gb3 accumula-
tion in both vascular smooth muscle (VSM) and endothelium in the
vasculature of Gla-knockout (Gla–/0) mice,7,8 a murine model for
Fabry disease.9 The increased vascular accumulation of Gb3 has
been associated with an increased propensity for thrombosis,7,10 as
well as increased atherogenesis,11 both of which are associated with
endothelial dysfunction.
Excess endothelial Gb3 is believed to contribute to endothelial
dysfunction associated with Fabry disease12 and Heare et al. demon-
strated that blunted endothelium-dependent relaxation is associated
with increased vascular Gb3 accumulation in older (19 months old)
Gla–/0 mice.13 The purpose of the present study was to further
characterize the vasculopathy associated with a murine model of Fabry
disease. Reactivity was performed in isolated vessels from wild-type
(Gla+/0) and Gla–/0 mice. Our results demonstrate that vascular
contractility to phenylephrine and serotonin, but not to U46619, were
blunted. Endothelium-dependent contraction and relaxation to ace-
tylcholine (ACh) also were attenuated, whereas receptor-independent
endothelium-dependent relaxation remained intact in Gla–/0 mice.
Furthermore, vascular reactivity was normalized in aortas from
Gla–/0 mice after removal of the endothelium. These changes in vascular
function were evident despite non-significant changes in consciously
measured blood pressure and heart rate. These results suggest that
vasculopathy in this model of Fabry disease is localized to the
endothelium despite the accumulation of GSLs throughout the
vasculature. More importantly, these observations suggest that the
endothelial defect may stem from excess GSLs affecting receptor
coupling, thereby extending our understanding of how excess
endothelial GSL accumulation may have a functional impact on
vascular function and pharmacology.
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METHODS
Mice
Male C57Bl/6 mice (wild-type or Gla+/0; 12–20 weeks old) were obtained
from Charles River (Wilmington, MA, USA) or Jackson Laboratories (Bar
Harbor, ME, USA). Male Gla-knockout (Gla–/0) mice9 were bred from mice
provided by Drs Ashok Kulkarni and Roscoe Brady (National Institutes of
Health, Bethesda, MD, USA). These mice were back-crossed at least five
generations to the C57Bl/6 strain. All mice were maintained on normal
chow in specific pathogen-free facilities.
The procedures performed in mice were in accordance with guidelines of
the University of Michigan Committee on the use and care of animals. The
University of Michigan Unit for Laboratory Animal Medicine provided
veterinary care. The University of Michigan is accredited by the American
Association of Laboratory Animal Care. The animal care and use programme
conformed to the standards in The Guide for the Care and Use of Laboratory
Animals (Department of Health, Education and Welfare Publication No.
(NIH) 86–23; http://www.nap.edu/readingroom/books/labrats/).
Direct blood pressure and heart rate measurements with 
radiotelemetry
Blood pressure and heart rate were measured in Gla+/0 and Gla–/0 mice as
described previously.14 Briefly, the left common carotid artery was cannu-
lated with the catheter of a telemetric blood pressure transducer (model
TAP20-C10; Data Sciences International, St Paul, MN, USA), securing the
body of the device in the abdominal cavity. Diastolic, systolic and mean
arterial pressures, as well as heart rate, were collected every 10 min continuously
for 3 weeks, beginning immediately after implantation. At the end of 3
weeks, three consecutive 28 h periods were averaged from each mouse and
a group mean was calculated. The rate–pressure product (mVO2), an
indicator of myocardial oxygen consumption, was calculated from systolic
pressure  heart rate.
Isometric force measurements
Vascular rings (2–3 mm in length), with or without endothelium, were
mounted in a myograph system (Danish Myo Technology, Aarhus, Denmark)
and bathed with warmed (37C), aerated (95% O2/5% CO2) physiological
salt solution (PSS; composition (in mmol/L): NaCl 130; KCl 4.7; KHPO4
1.18; MgSO4 1.17; CaCl2 1.6; NaHCO3 14.9; dextrose 5.5; CaNa2 EDTA
0.03). Carotid rings were denuded of endothelium using a human hair;
thoracic aortic rings were denuded of endothelium by perfusing the rings
with 100 L of 0.1% Triton in phosphate-buffered saline (PBS).15 Carotid rings
were set at 250 mg passive tension, whereas thoracic aortic rings were set
at 700 mg passive tension. These passive tensions were chosen based on
previous studies in the carotid artery16 and thoracic aorta.17 Arterial preparations
were equilibrated for 1 h, with washes every 20 min. Prior to experimental
protocols, rings were subjected to a wake-up protocol consisting of two
consecutive contractions with KPSS (composition (in mmol/L): NaCl 14.7;
KCl 100; KHPO4 1.18; MgSO4 1.17; CaCl2 1.6; NaHCO3 14.9; dextrose 5.5;
CaNa2 EDTA 0.03) and phenylephrine (PE; 10
–6 mol/L), with washes
between each KPSS contraction. After the PE contraction reached a plateau
in the thoracic aortas, endothelial integrity was tested with 10–5 mol/L ACh.
The carotid rings were not exposed to ACh during the wake-up protocol
because previous exposure of the arterial preparations to ACh or sodium




Carotid arteries were used to evaluate endothelium-dependent contractions
because aortas do not have as robust an endothelium-dependent contraction
as do carotid arteries.19 All equilibration and reactivity in the carotid rings
(KPSS- and ACh-induced contractions) were performed in the presence of
3  10–4 mol/L NG-nitro-l-arginine (l-NNA). After the wake-up protocol
was performed, the PE contraction was washed out. Because of the biphasic
nature of the ACh-mediated contraction, only a single concentration of ACh
(10–5 mol/L) was used on the arterial preparations.19 A total of 10 mice was
used to determine reactivity in the carotid arteries.
Vascular smooth muscle contractility
Thoracic aortas were used to evaluate VSM reactivity in endothelium-intact
rings in the presence or absence of 3  10–4 mol/L l-NNA or in endothelium-
denuded rings. After the wake-up protocol, cumulative concentrations of
PE (10–9 to 10–5 mol/L), serotonin (5-HT; 10–9 to 10–5 mol/L) or the prostag-
landin (PG) H2/thromboxane (TX) A2 (TP) receptor agonist U46619 (10
–11
to 3  10–7 mol/L) were added to the bath to establish a concentration–
response curve. Contractions to PE, 5-HT or U46619 were expressed as a
percentage of the second KPSS contraction. Reactivity to 5-HT and U46619
was determined in a group of aortas different from those used to investigate
PE reactivity.
Endothelium-dependent and -independent relaxation
In rings of thoracic aorta in which a PE concentration–response curve was
constructed, the PE contraction was washed out and the EC80 was calculated
for PE in each individual ring. The individual EC80 values for PE were used
to contract individual rings, which were allowed to reach a stable plateau
response. Acetylcholine (10–10 to 10–5 mol/L), ionomycin (10–10 to 3 
10–7 mol/L) or SNP (10–11 to 10–6 mol/L) was added cumulatively to the bath
to examine endothelium-dependent (ACh and ionomycin) or -independent
(SNP) relaxation. Acetylcholine, ionomycin and SNP relaxation was
expressed as a percentage of the contraction to the EC80 of PE. Reactivity
to ACh and SNP was determined in the same rings, whereas ionomycin
reactivity was determined in separate rings that did not receive ACh or SNP.
Separate reactivity to all agonists also was examined in the presence of l-NNA
(10–4 mol/L). In addition, PE, ACh and SNP reactivity was determined again
in separate endothelium-denuded rings.
Chemicals
Phenylephrine, 5-HT, ACh, SNP, l-NNA, Triton and all salts for PSS were
purchased from Sigma Chemical (St Louis, MO, USA). U46619 was
purchased from Cayman Chemical (Ann Arbor, MI, USA). Ionomycin
was purchased from Calbiochem (La Jolla, CA, USA).
Data and statistical analysis
Agonist EC50 values were calculated using non-linear regression analysis
with the algorithm (effect = maximum response/1 + (EC50/agonist concen-
tration)) in the computer program GraphPad Prism (San Diego, CA, USA).
Hill slope values were also derived from GraphPad Prism. The EC80 values
for PE were calculated from the equation:
log EC50 = log ECF – (1/Hill slope)  log(F/(100 – F))
where F = 80.
Data are expressed as the mean±SEM. Blood pressure, heart-rate and rate–
pressure products were analysed using two-way anova. Concentration–
response data were analysed using two-way anova to compare the concen-
tration–response curves between groups. Bonferonni’s post hoc test was used
to assess differences at individual points on the concentration–response
curves if the results of the two-way anova comparison between curves were
P < 0.05. One-way anova was used to evaluate differences between groups
in endothelium-dependent contractions. Differences in KPSS contractions,
EC50 and Emax between two groups were analysed by Student’s t-test. P < 0.05
was considered significant.
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RESULTS
Blood pressure and heart rate in Gla+/0 and Gla–/0 mice
Blood pressure and heart rate measured in Gla+/0 and Gla–/0 mice are
shown in Figs 1 and 2. Diastolic (Fig. 1a), systolic (Fig. 1b) and
mean arterial pressure (Fig. 1c) fluctuated due to circadian rhythms,
but did not differ between the two groups over the 28 h period meas-
ured, suggesting the Gla–/0 mice were not hypertensive. Heart rate
(Fig. 2) also fluctuated throughout the 28 h period due to circadian
rhythms. Heart rate in Gla–/0 mice was higher compared with Gla+/0
mice during the dark cycle, but the difference was not statistically
significant. The rate–pressure product (mVO2), a calculated index
of myocardial oxygen consumption (Fig. 2b), also tended to be
higher in Gla–/0 mice compared with Gla+/0 mice during the dark
cycle, although the difference was not significant, suggesting that
hearts in Gla–/0 mice may be working harder to maintain perfusion
pressure.
Vascular contractility with PE, 5-HT and U46619
Phenylephrine
The vascular contraction mediated by 100 mmol/L KPSS was
equivalent in aortas from Gla+/0 and Gla–/0 mice (1708 ± 107 vs
1496 ± 93 mg, respectively; n = 16; P > 0.05). In the presence of l-
NNA, the KPSS-induced contractions in Gla+/0 (n = 12) and Gla–/0
(n = 13) mice were 2078 ± 99 and 2056 ± 93 mg, respectively
(P > 0.05). After endothelial denudation, KPSS-induced contrac-
tions in Gla+/0 and Gla–/0 mice were 1065 ± 123 and 1007 ± 118 mg,
respectively (n = 5; P > 0.05).
Phenylephrine caused a concentration-dependent contraction in
isolated endothelium-intact aortic rings from both Gla+/0 and Gla–/0
mice (Fig. 3). Phenylephrine contractility in untreated, endothelium-
intact vessels (Fig. 3a) was approximately twofold less sensitive in
aortas from Gla–/0 compared with Gla+/0 mice (Table 1). In addition,
maximal contraction (Emax) to PE in aortas from Gla
–/0 mice was sig-
nificantly less than that in aortas from Gla+/0 mice (92.9 ± 3.7 vs
107.9 ± 4.0%, respectively; P < 0.05). Phenylephrine contractility
in the presence of l-NNA (Fig. 3b) was still less sensitive (~1.6-
fold less) in aortas from Gla–/0 compared with Gla+/0 mice (Table 2),
Fig. 1 Conscious (a) diastolic, (b) systolic and (c) mean arterial (MAP) blood pressures measured during a 28 h light–dark cycle by telemetry in wild-type
(Gla+/0; n = 8; ) or Gla-knockout (Gla–/0; n = 9; ) mice. P > 0.05 by two-way anova.
Fig. 2 (a) Heart rate and (b) calculated myocardial oxygen consumption
(mVO2) or rate–pressure product obtained from measurements derived from
a telemetric blood pressure transducer in wild-type (Gla+/0; n = 8; ) or Gla-
knockout (Gla–/0; n = 9; ) mice. P > 0.05 by two-way anova.
Table 1 Potency of agonists in vascular reactivity of thoracic aortas with
an intact endothelium from wild-type (Gla+/0) or Gla-knockout (Gla–/0) mice
Agonist –log EC50 (mol/L)
Gla+/0 Gla–/0
PE 6.99 ± 0.05 (16) 6.72 ± 0.05* (16)
5-HT 7.08 ± 0.03 (8) 6.89 ± 0.04* (8)
U46619 8.77 ± 0.02 (8) 8.70 ± 0.02* (8)
ACh 7.43 ± 0.05 (7) 7.37 ± 0.10 (7)
Ionomycin 7.98 ± 0.03 (6) 8.01 ± 0.02 (6)
SNP 8.27 ± 0.10 (7) 7.93 ± 0.05* (7)
Data are the mean±SEM, with the number of animals given in parentheses.
*P < 0.05 compared with Gla+/0 (Student’s t-test).
EC50 values are expressed as the –log EC50 for each agonist.
PE, phenylephrine; ACh, acetylcholine; 5-HT, serotonin; SNP, sodium
nitroprusside.
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whereas maximal contraction to PE did not differ in Gla+/0 and
Gla–/0 mice in the presence of l-NNA (122.5 ± 3.1 vs 121.1 ± 3.6%,
respectively; P > 0.05). Figure 3c shows PE reactivity in endothelium-
denuded aortas from Gla+/0 and Gla–/0 mice. The PE-induced
contractions were equivalent in aortas from Gla+/0 and Gla–/0 mice,
as demonstrated by similar log EC50 values (Table 3), as well as
equivalent Emax values (189.9 ± 22.6 vs 198.0 ± 24.8%, respectively;
P > 0.05).
Serotonin
The vascular contraction mediated by 100 mmol/L KPSS for 5-HT
and U46619 reactivity did not differ in endothelium-intact rings
from Gla+/0 and Gla–/0 mice (1225 ± 109 vs 1241 ± 101 mg, respec-
tively; n = 8; P > 0.05). In addition, KPSS-induced contractions did
not differ between Gla+/0 and Gla–/0 mice in the presence of l-NNA
(1414 ± 60 vs 1455 ± 73 mg, respectively; n = 6; P > 0.05) or after
endothelium denudation (1064 ± 76 vs 1043 ± 82 mg, respectively;
n = 5; P > 0.05).
Serotonin produced concentration-dependent contraction of aortic
rings (Fig. 4). Similar to PE, 5-HT contractility in endothelium-
intact aortic rings (Fig. 4a) from Gla–/0 mice was significantly less
than that of aortas from Gla+/0 mice (Table 1). Maximal contraction
(Emax) to 5-HT in aortas from Gla
–/0 mice was significantly less than
that of aortic rings from Gla+/0 mice (119.4 ± 5.7 vs 138.3 ± 2.9%,
respectively; P < 0.05). In the presence of l-NNA (Fig. 4b), the
difference in Emax between Gla
+/0 and Gla–/0 mice was no longer
significant (116.3 ± 1.7 vs 108.1 ± 5.3%, respectively; P > 0.05), but
the difference in sensitivity was maintained (Table 2). Similarly, when
the endothelium was removed (Fig. 4c), the Emax to 5-HT was no longer
significantly different between Gla+/0 and Gla–/0 mice (161.1 ± 5.9
vs 162.8 ± 12.2%, respectively; P > 0.05); however, unlike responses
to PE, the log EC50 to 5-HT in endothelium-denuded rings remained
less in Gla–/0 mice than in Gla+/0 mice (Table 3).
The TP receptor agonist U46619
The third vasopressor tested in the present study, namely U46619,
also caused concentration-dependent contractions of aortic rings
from both Gla+/0 and Gla–/0 mice (Fig. 5). However, Emax contractility
did not differ between Gla+/0 and Gla–/0 mice regardless of the pres-
ence of an intact endothelium (177.9 ± 5.3 vs 169.4 ± 7.0%, respec-
tively; P > 0.05; Fig. 5a:), l-NNA (132.7 ± 4.0 vs 142.4 ± 4.7%,
respectively; P > 0.05; Fig. 5b) or after removal of the endothelium
(193.0 ± 11.1 vs 211.5 ± 19.9%, respectively; P > 0.05; Fig. 5c).
The EC50 for U46619 in endothelium-intact aortic rings from
Fig. 3 Phenylephrine-mediated vascular contraction in endothelium-intact aortic rings from wild-type (Gla+/0; filled symbols) or Gla-knockout (Gla–/0; open
symbols) mice (a) alone without any pharmacological intervention, (b) in the presence of 10–4 mol/L NG-nitro-l-arginine or (c) in endothelium-denuded
preparations. Data are expressed as a percentage of the contraction elicited by 100 mmol/L KCl-containing physiological salt solution and show the mean±SEM
(n = 5–16). *P < 0.05 compared with Gla+/0 (two-way anova followed by Bonferonni’s post hoc test).
Table 2 Potency of agonists in vascular reactivity of thoracic aortas with
an intact endothelium from wild-type (Gla+/0) or Gla-knockout (Gla–/0) mice
in the presence of 3  10–4 mol/L NG-nitro-l-arginine
Agonist –log EC50 (mol/L)
Gla+/0 Gla–/0
PE 7.37 ± 0.04 (12) 7.17 ± 0.05* (13)
5-HT 7.19 ± 0.02 (6) 6.96 ± 0.04* (6)
U46619 9.08 ± 0.03 (6) 8.95 ± 0.03* (6)
ACh 6.57 ± 0.20 (7) 6.76 ± 0.31 (7)
Ionomycin 8.01 ± 0.31 (5) 7.76 ± 0.21 (6)
SNP 9.07 ± 0.13 (5) 9.11 ± 0.02* (5)
Data are the mean±SEM, with the number of animals given in parentheses.
*P < 0.05 compared with Gla+/0 (Student’s t-test).
EC50 values are expressed as the –log EC50 for each agonist.
PE, phenylephrine; ACh, acetylcholine; 5-HT, serotonin; SNP, sodium
nitroprusside.
Table 3 Potency of agonists in vascular reactivity of endothelium-denuded
thoracic aortas from wild-type (Gla+/0) or Gla-knockout (Gla–/0) mice
Agonist –log EC50 (mol/L)
Gla+/0 Gla–/0
PE 7.49 ± 0.10 (5) 7.42 ± 0.10 (5)
5-HT 7.38 ± 0.04 (6) 7.15 ± 0.05* (5)
U46619 9.16 ± 0.04 (6) 9.13 ± 0.02 (5)
ACh 8.85 ± 0.95 (5) 7.57 ± 0.86 (5)
Ionomycin ND ND
SNP 9.07 ± 0.02 (5) 9.11 ± 0.02* (5)
Data are the mean±SEM, with the number of animals given in parentheses.
*P < 0.05 compared with Gla+/0 (Student’s t-test).
EC50 values are expressed as the –log EC50 for each agonist.
PE, phenylephrine; ACh, acetylcholine; 5-HT, serotonin; SNP, sodium
nitroprusside; ND, not determined.
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Gla–/0 mice was minimally different, yet still significant, compared
with the EC50 for U46619 in similar preparations from Gla
+/0 mice
(Table 1). Similar observations were made for U46619 contractility
in the presence of l-NNA (Table 2). However, removing the
endothelium resulted in similar EC50 values for U46619 in aortic
rings from both Gla+/0 and Gla–/0 mice (Table 3).
Endothelium-dependent contraction with ACh
Endothelium-dependent contraction to ACh was examined in iso-
lated carotid arteries from Gla+/0 and Gla–/0 mice (Fig. 6). The carotid
arteries were used because they display a much more robust endothelium-
dependent contraction to ACh compared with the aorta.19 The
KPSS-induced contractions in endothelium-intact carotid rings from
Gla+/0 and Gla–/0 mice were equivalent (514 ± 56 vs 490 ± 46 mg,
respectively; n = 5). In carotid arteries, under baseline resting
conditions, ACh (10–5 mol/L), in the presence of 3  10–4 mol/L l-NNA,
caused a contraction that was absent in endothelium-denuded
arteries. However, the endothelium-dependent contraction elicited
by ACh was significantly less in carotid arteries from Gla–/0 mice
(~49% less) compared with Gla+/0 mice.
Receptor-mediated endothelium-dependent relaxation 
with ACh
Endothelium-dependent relaxation to ACh also was examined in
aortas isolated from Gla+/0 and Gla–/0 mice and precontracted with
the EC80 for PE calculated individually for each ring on the basis of
the PE concentration–response curve. Aortic rings from Gla–/0 mice
relaxed significantly less than rings from Gla+/0 mice (Emax 62.5 ± 6.3
vs 83.3 ± 2.9%, respectively; Fig. 7a). The ACh responses are
endothelial nitric oxide synthase (eNOS) and endothelium dependent,
because both l-NNA (Fig. 7b) and endothelium denudation (Fig. 7c)
prevented any ACh-mediated relaxation in precontracted aortic rings
from Gla+/0 and Gla–/0 mice.
Fig. 4 Serotonin (5-HT)-mediated vascular contraction in endothelium-intact mouse aortic rings from wild-type (Gla+/0; filled symbols) or Gla-knockout
(Gla–/0; open symbols) mice (a) alone without any pharmacological intervention, (b) in the presence of 10–4 mol/L NG-nitro-l-arginine or (c) in endothelium-
denuded preparations. Data are expressed as a percentage of the contraction elicited by 100 mmol/L KCl-containing physiological salt solution and show the
mean±SEM (n = 5–8). *P < 0.05 compared with Gla+/0 (two-way anova followed by Bonferonni’s post hoc test).
Fig. 5 Vascular contraction mediated by the thromboxane A2/prostaglandin H2 (TP) receptor agonist U46619 in endothelium-intact mouse aortic rings from
wild-type (Gla+/0; filled symbols) or Gla-knockout (Gla–/0; open symbols) mice (a) alone without any pharmacological intervention, (b) in the presence of
10–4 mol/L NG-nitro-l-arginine or (c) in endothelium-denuded preparations. Data are expressed as a percentage of the contraction elicited by 100 mmol/L
KCl-containing physiological salt solution and show the mean±SEM (n = 5–8). *P < 0.05 compared with Gla+/0 (two-way anova followed by Bonferonni’s
post hoc test).
 
Fig. 6 Endothelium-dependent contraction mediated by 10–5 mol/L acetyl-
choline in endothelium-intact (+ENDO) and -denuded (–ENDO) carotid
artery rings from wild-type (Gla+/0; ) or Gla-knockout (Gla–/0; ) mice in
the presence of 3  10–4 mol/L NG-nitro-l-arginine. Data are the mean±SEM
(n = 5 in each group). *P < 0.05 compared with Gla+/0; †P < 0.05 compared
with Gla+/0 –ENDO (one-way anova). 
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Non-receptor-mediated endothelium-dependent 
relaxation with ionomycin
The calcium ionophore ionomycin was used to induce non-receptor-
mediated eNOS-dependent relaxations in endothelium-intact vessels
precontracted with an EC80 of PE (Fig. 8). Ionomycin-induced
relaxation (Fig. 8a) did not differ between vessels from Gla+/0
(log EC50 = –7.98 ± 0.03 mol/L; Emax = 95.5 ± 2.1%) and Gla
–/0
(log EC50 = –8.01 ± 0.02 mol/L; Emax = 94.5 ± 1.7%) mice. Ionomycin
caused a slight relaxation in precontracted endothelium-intact aortic
rings from Gla+/0 and Gla–/0 mice incubated with l-NNA (Fig. 8b),
but no significant differences existed between the two groups in
terms of the sensitivity or maximal response to ionomycin in the
presence of l-NNA.
Endothelium-independent relaxation with SNP
Sodium nitroprusside mediated a concentration-dependent
endothelium-independent relaxation in thoracic aortas isolated from
Gla+/0 and Gla–/0 mice. In endothelium-intact rings, the SNP-induced
relaxation was less in rings from Gla–/0 compared with Gla+/0 mice
(Table 1). Vessels exposed to the NOS inhibitor l-NNA were sig-
nificantly more sensitive to SNP compared with respective vessels
with an intact endothelium and in the absence of l-NNA (Table 2).
Similarly, endothelium-denuded aortas exhibited increased sensitiv-
ity to SNP compared with their untreated, endothelium-intact
counterparts (Table 3) and were similar in sensitivity to l-NNA-
treated vessels.
DISCUSSION
Fabry disease has a complex cardiovascular phenotype. Premature
mortality is more often the result of stroke and myocardial infarc-
tions.20 Informative clinical studies in Fabry disease patients have
documented both macro- and microvascular dysfunction, suggest-
ing that the pathophysiology may be highly complex.21,22 The -
galactosidase A knockout mouse (Gla–/0) provides a potentially useful
tool to study these cardiovascular phenomena. Indeed, our group has
reported that these mice are more susceptible to oxidant-induced
thrombosis and accelerated atherogenesis.7,11 In the present study, we
used this model to ascertain the role of the endothelium in large
vessel reactivity.
We report several novel observations in this Gla–/0 murine model
of Fabry disease. First, abnormal vasopressor contractility to PE and
5-HT; aortas from Gla–/0 mice are less sensitive to these agents than
wild-type (Gla+/0) aortas but exhibit normal responses to the TP
receptor agonist or when the endothelium is removed. Second,
endothelium-dependent contraction is significantly less in Gla–/0
compared with Gla+/0 carotid arteries. Third, impaired endothelium-
dependent relaxation is not observed when a calcium ionophore is
used to mediate endothelium-dependent relaxation. These observa-
tions are important because the defects observed in this murine
model of Fabry disease demonstrate a complexity of the reactivity
 
Fig. 7 Acetylcholine-mediated endothelium-dependent relaxation in endothelium-intact mouse aortic rings from wild-type (Gla+/0; filled symbols) or Gla-
knockout (Gla–/0; open symbols) mice (a) alone without any pharmacological intervention, (b) in the presence of 10–4 mol/L NG-nitro-l-arginine or (c) in
endothelium-denuded preparations. Data are expressed as a percentage of the contraction elicited by the EC80 for phenylephrine and show the mean±SEM
(n = 5–7). *P < 0.05 compared with Gla+/0 (two-way anova followed by Bonferonni’s post hoc test).
Fig. 8 Ionomycin-induced endothelial nitric oxide synthase-dependent
relaxation in endothelium-intact aortic rings from wild-type (Gla+/0; filled
symbols) or Gla-knockout (Gla–/0; open symbols) mice precontracted with
an EC80 concentration of phenylephrine (PE) (a) alone without any pharma-
cological intervention or (b) in the presence of 10–4 mol/L NG-nitro-l-
arginine. Data are the mean±SEM (n = 5–6). P > 0.05 (two-way anova).
1162 JL Park et al.
© 2008 The Authors
Journal compilation © 2008 Blackwell Publishing Asia Pty Ltd
that can be attributed entirely to the endothelium, even though ele-
vated Gb3 levels occur in the other vascular cell types.7,13
In many vascular diseases, such as hypertension and diabetes,
VSM vasopressor sensitivity is increased, whereas endothelium-
dependent relaxation is diminished.23–26 Our data were surprising
because abnormal endothelium-dependent relaxation was observed
but a concomitant increased sensitivity to vasopressor activity was
absent in the presence of endothelium, as illustrated by decreased
sensitivity to PE or 5-HT, whereas TP receptor-mediated VSM con-
traction with U46619 was similar in Gla–/0 and Gla+/0 mice.
How this anomaly developed in our mouse model of Fabry disease
is unclear, but we speculate on several mechanisms that may par-
tially explain our observations. If basal NO production is higher in
Gla–/0 mice, then VSM contraction would be inhibited. Furthermore,
if agonist-stimulated NO production is less in Gla–/0 mice, for what-
ever reason, endothelium-dependent relaxation would also be inhib-
ited or diminished. However, the persistence of decreased sensitivity
to vasopressor in the presence of l-NNA does not support that
hypothesis, suggesting that the endothelium may be producing
another factor to cause endothelium-dependent relaxation after
stimulation with ACh. Prostaglandin I2, which mediates endothelium-
dependent relaxation by activation of cAMP in VSM,27 is a potential
mechanism by which our anomalous reactivity may be occurring.
However, whether cyclo-oxygenase-derived products have any
role in the vascular dysfunction or are in some way regulated by
glycosphingolipids is yet to be determined.
Alternatively, on a more cellular level, in cells subjected to
pathologically increased levels of Gb3, excess Gb3 content may be
present in compartments outside the lysosome, including lipid rafts
or caveolae. Recently, we reported that Gb3 and other globo series
GSLs are present in higher concentrations in caveolae from Gla–/0
compared with Gla+/0 endothelial cells.28 These changes in GSLs increase
as a function of age and are accompanied by corresponding decreases
in cholesterol. In addition, GSL concentrations in caveolae change
dynamically after endothelial cells are exposed to recombinant
-galactosidase A or the glucosylceramide synthase inhibitor d-threo-
ethylenedioxyphenyl-2-palmitoylamino-3-pyrillidino-propanol. Modula-
tion of cellular GSL content regulates bradykinin-induced src kinase
and phospholipase C activation.29,30 Conversely, increased Gb3
accumulation in endothelial cells may inhibit receptor-induced
signalling responsible for activation of eNOS. The observation of
endothelium-dependent relaxation with the calcium ionophore
ionomycin supports this potential mechanism because the ionophore
relaxation is normal in aortas from Gla–/0 compared with Gla+/0 mice,
whereas the receptor-induced endothelium-dependent relaxation to
ACh is attenuated in aortas from Gla–/0 mice.
Because these caveolar domains are enriched with and regulate
eNOS, accumulated caveolar GSL associated with Fabry disease
may conceivably alter eNOS activation by one of two mechanisms.
First, eNOS and caveolin interactions are affected by excess Gb3
or a related sphingolipid or, alternatively, by secondary changes in
other raft-associated lipids. Second, receptor coupling to down-
stream mediators may be affected, because sphingolipid, as well as
cholesterol, content in lipid rafts or caveolae can modulate the
fluidity of these signalling ‘hot spots’.31 Our data appear to support the
latter mechanism because eNOS activation independent of a receptor
is normal, suggesting that any interactions between eNOS and
caveolin-1 are not affected by increased caveolar Gb3 content. However,
further studies are needed to demonstrate that receptor coupling is
affected by excess endothelial Gb3 in this mouse model of Fabry disease.
Our endothelium-dependent contraction and relaxation data combined
are consistent with the hypothesis that receptor coupling is affected in
this mouse model of Fabry disease, because both are attenuated in
Gla–/0 mice and, in particular, because endothelium-dependent contrac-
tions, in the face of endothelial dysfunction, should be augmented.
Our data indicate that, whatever the mechanism may be, changes
in vascular function in the Gla–/0 mice are localized to the endothe-
lium. This conclusion is supported by two main observations. First,
most of the vascular contractility to vasopressor is close to normal
after endothelium denudation. Second, endothelium-dependent con-
traction is significantly attenuated in Gla–/0 mice, a phenomenon that
is due to the paracrine release of a TP receptor agonist from the
endothelium.32 However, direct stimulation of VSM contraction with
the TP receptor agonist U46619 did not reveal any differences
between Gla–/0 and Gla+/0 mice.
In conclusion, we demonstrate that the vasculopathy associated
with Gla–/0 mice occurs at a younger age than reported previously13
and that the early vasculopathy is localized to the endothelium.
Importantly, the vasculopathy reported here may be a result of
impaired receptor signalling rather than impaired eNOS activity.
These findings provide insight into how early vasculopathy may
develop in Fabry disease, but they also suggest that glycosphingolipid
metabolism may play a subtle, yet significant, role in the regulation
of receptor-mediated signalling.
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